

Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study.

Alejandro Durán-Méndez, Alma Delia Aguilar-Arroyo, Emiliano Vivanco-Gómez, Eduardo Nieto-Ortega, Daniela Pérez-Ortega, Cristian Jiménez-Pérez, Karla Y. Hernández-Skewes, Guillermo Montiel-Bravo, Oscar J. Roque-Reyes, Fernanda Romero-Lechuga, Diana Medina-Santos, Perla Oriana-Román, Jorge Rafael Flores-Hernández, Juan Daniel Méndez-Coca, Daniela Montaña-Olmos, Karla Cecilia Farfán-Lazos, Miranda Tobón-Cubillos, América Viveros-Hernández, Fernando Sevilla-Castillo, Ángel Raúl Hernández-Romero, Shannat Ortega-Rodríguez, Aldo Christiaan Jardínez-Vera, María Antonieta Solís-González, Antonio Ramos de la Medina, Laura Martínez Pérez-Maldonado, Elizabeth Lagunes-Lara, Miguel Cova-Bonilla, Alberto N. Peón

Supplementary Table S1. Dosing strategy.

	<i><400 mg of Tocilizumab</i>	<i>400-800 mg of Tocilizumab</i>	<i>>800 mg of Tocilizumab</i>	<i>Average dose</i>	<i>Patients receiving adittional doses</i>
<i>Critically-ill</i>	2 (22.2%)	2 (22.3%)	5 (55.5%)	790 mg	22%
<i>Severely-ill</i>	5 (12.8%)	24 (61.5%)	10 (25.6%)	790 mg	26%
<i>Moderately-ill</i>	8 (25.8%)	18 (58%)	5 (16.12%)	550 mg	24%